Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 7/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.59 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024688 | 1.00 | KMT2A (1.00) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL10981054 | 0.85 | ALDH1A1 (1.00) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL6541748 | 0.85 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL6541745 | 0.85 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL13854024 | 0.85 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL9767814 | 0.81 | ALDH1A1 (0.78) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL31530581 | 0.81 | RAB9A (0.77) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL31530568 | 0.81 | RAB9A (0.77) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL6037174 | 0.80 | KMT2A (0.66) | KMT2AMEN1RAB9ANPC1MAPT | |
| SCHEMBL6037177 | 0.80 | KMT2A (0.66) | KMT2AMEN1RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | claimed |
| WO-2009100323-A2 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY (US) | 2009-08-13 | — | — | WO | claimed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | disclosed |
| WO-2009100323-A2 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
| US-5006548-A | Hyaluronidase inhibitors, antiallergens, immunomodulators | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0153850-B1 | ACRYLAMIDOBENZOIC ACID DERIVATIVES AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | NAAA, ELANE, APEH | KMT2A 1670/4885MEN1 3484/4885RAB9A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.